Results 121 to 130 of about 100,721 (313)

Psilocybin as a novel treatment for chronic pain

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey   +3 more
wiley   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

open access: yesBritish Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

open access: yesBritish Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller   +3 more
wiley   +1 more source

Cannabigerol reverses mechanical allodynia through α2A‐adrenergic modulation of thalamocortical signaling in chemotherapy‐induced neuropathy

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade   +7 more
wiley   +1 more source

Differential effects of ketamine enantiomers on EEG parameters including the gamma‐delta shift phenomenon

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Ketamine consists of two enantiomers, (R)‐ketamine and (S)‐ketamine, which exhibit distinct pharmacological properties. Currently, only the (S)‐enantiomer has been approved for the treatment of major depressive disorder, whereas recent clinical studies have failed to demonstrate an antidepressant effect for (R)‐ketamine.
Szabolcs Koncz   +4 more
wiley   +1 more source

Systematic Multiplatform Discovery of Methylation Markers Enables Non‐Invasive Early Detection of Endometrial Cancer

open access: yesCancer Science, EarlyView.
We identified key endometrial cancer DNA methylation biomarkers (ZNF626, GRIA4, SPDYA) from cervical cells. The model achieved high endometrial cancer sensitivity and detected 92.86% of Stage I endometrial cancers using TCT samples. ABSTRACT Endometrial cancer, the most common gynecological malignancy with an annual increase of 1%–3%, lacks suitable ...
Yan Cai   +10 more
wiley   +1 more source

Neuronal hyperexcitability: A key to unraveling hippocampal synaptic dysfunction in Lafora disease

open access: yesEpilepsia, EarlyView.
Abstract Background and Objective Lafora disease (LD) is a rare progressive disorder caused by mutations in the EPM2A or EPM2B genes, characterized by the accumulation of Lafora bodies, drug‐resistant epilepsy, and cognitive decline. To investigate the early molecular mechanisms of LD, we studied electrophysiological changes in the dentate gyrus (DG ...
Cinzia Costa   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy